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ABSTRACT Studying HIV-infected individuals who control HIV replication (elite control-
lers [ECs]) enables exploration of effective anti-HIV immunity. HIV Env-speciﬁc and non-
Env-speciﬁc antibody-dependent cellular cytotoxicity (ADCC) may contribute to protec-
tion from progressive HIV infection, but the evidence is limited. We recruited 22 ECs and
matched them with 44 viremic subjects. HIV Env- and Vpu-speciﬁc ADCC responses in
sera were studied using a novel enzyme-linked immunosorbent assay (ELISA)-based di-
meric recombinant soluble FcRIIIa (rsFcRIIIa)-binding assay, surface plasmon reso-
nance, antibody-dependent natural killer (NK) cell activation assays, and ADCC-mediated
killing assays. ECs had higher levels of HIV Env-speciﬁc antibodies capable of binding
FcRIIIa, activating NK cells, and mediating granzyme B activity (all P  0.01) than vire-
mic subjects. ECs also had higher levels of antibodies against a C-terminal 13-mer Vpu
peptide capable of mediating FcRIIIa binding and NK cell activation than viremic sub-
jects (both P  0.05). Our data associate Env-speciﬁc and Vpu epitope-speciﬁc ADCC in
effective immune responses against HIV among ECs. Our ﬁndings have implications for
understanding the role of ADCC in HIV control.
IMPORTANCE Understanding immune responses associated with elite control of HIV
may aid the development of immunotherapeutic and vaccine strategies for control-
ling HIV infection. Env is a major HIV protein target of functional antibody responses
that are heightened in ECs. Interestingly, EC antibodies also target Vpu, an accessory
protein crucial to HIV, which degrades CD4 and antagonizes tetherin. Antibodies
speciﬁc to Vpu are a common feature of the immune response of ECs that may
prove to be of functional importance to the design of improved ADCC-based immu-
notherapy and preventative HIV vaccines.
KEYWORDS ADCC, elite controller, FcR, Vpu
The immune mechanisms of human immunodeﬁciency virus (HIV) control are notclearly understood. Investigation of HIV-infected individuals who naturally control
HIV infection, known as elite controllers (ECs), may provide clues to the immune
mechanisms facilitating HIV control. ECs represent 0.5% of HIV-infected individuals
Received 1 May 2017 Accepted 19 June 2017
Accepted manuscript posted online 12 July
2017
CitationMadhavi V, Wines BD, Amin J, Emery
S, ENCORE1 Study Group, Lopez E, Kelleher A,
Sydney LTNP Study Group, Center RJ, Hogarth
PM, Chung AW, Kent SJ, Stratov I. 2017. HIV-1
Env- and Vpu-speciﬁc antibody-dependent
cellular cytotoxicity responses associated with
elite control of HIV. J Virol 91:e00700-17.
https://doi.org/10.1128/JVI.00700-17.
Editor Guido Silvestri, Emory University
Copyright © 2017 American Society for
Microbiology. All Rights Reserved.
Address correspondence to Stephen J. Kent,
skent@unimelb.edu.au.
A.W.C., S.J.K., and I.S. are joint last authors.
PATHOGENESIS AND IMMUNITY
crossm
September 2017 Volume 91 Issue 18 e00700-17 jvi.asm.org 1Journal of Virology
 o
n
 August 1, 2018 by UQ Library
http://jvi.asm.org/
D
ow
nloaded from
 
and have repeatedly undetectable HIV plasma viremia in the absence of antiretroviral
therapy (ART) (1).
Numerous factors are likely involved in the control of HIV infection, including viral
and host genetics, which cannot be easily manipulated in a broad-based vaccine or
cure strategy. Particular HLA I alleles, such as HLA-B27, HLA-B57, and HLA-B51, are
approximately twice as common in ECs as in people with progressive HIV infection
(2–4). HIV epitopes restricted by these alleles (especially targeting Gag) mediate potent
HIV suppression (1, 5). HIV-speciﬁc CD4 T-cell responses have higher functional avidities
in ECs (6), but somewhat counterintuitively, neutralizing antibodies (NAbs) are found
less frequently in ECs than in viremic subjects (7, 8). We previously reported that
HIV-infected slow progressors have higher and broader antibody-dependent cellular
cytotoxicity (ADCC) responses than people with progressive HIV (9, 10). Lambotte et al.
have shown high HIV Env-speciﬁc ADCC responses in a heterogenous group of HIV
controllers (11). However, more data on the role of ADCC in elite control of HIV would
facilitate the designing of strategies to control and prevent HIV.
Most antibody-related HIV vaccine research has focused on targeting the envelope
(Env) protein of HIV. However, Env has proven to be a difﬁcult target due to its wide
diversity across the globe, its high mutation rate, and often poor access of NAbs to
critical conserved epitopes (12, 13). Since the partial efﬁcacy seen in the RV144 trial and
the results of the subsequent post hoc analyses, HIV-speciﬁc ADCC responses have
gained importance as potential targets for prevention and control of infection (14).
These responses have several possible advantages over NAbs, in that they can target
cells within which HIV is replicating and they can also target non-Env proteins such as
Pol and Vpu (10, 15).
In addition to Env, immune responses against the HIV regulatory transmembrane
protein Vpu are of interest as potentially effective responses. We have previously
identiﬁed HIV-speciﬁc NK cell activation by antibodies targeting the C-terminal portion
of the Vpu protein and also showed that Vpu-speciﬁc ADCC responses were more
common in subjects with slowly progressive HIV infection (16). Chen et al. showed that
polymorphisms in the terminal sequence of Vpu are associated with EC status com-
pared with HIV viremic subjects, although the drivers of these polymorphisms were not
identiﬁed, other than that they was independent of KIR2DL2 status (17).
To investigate a potential role for ADCC in HIV control, we enrolled 22 ECs and
compared these to a matched cohort of 44 viremic subjects and studied Env- and
Vpu-speciﬁc ADCC responses.
RESULTS
ECs have high levels of total HIV Env-speciﬁc and Vpu-speciﬁc IgG antibodies
compared to those of viremic subjects. ECs are a model to study HIV control (9, 18,
19), and we recruited 22 ECs to provide serum samples and matched these subjects to
44 viremic subjects. The clinical characteristics of the subjects are shown in Tables 1 and
2. Since functional antibody responses have been associated with the control of HIV in
other settings, we studied antibody responses to both HIV Env and Vpu in ECs. Env is
a common target for functional antibody responses (7), and we previously observed
Vpu-speciﬁc functional antibody responses in a subset of HIV-infected subjects (10). In
the current study, we ﬁrst analyzed total antibody responses and found that sera from
22 ECs had higher levels of HIV Env-speciﬁc IgG antibodies than those from the 44
matched viremic subjects (P  0.0001) (Fig. 1A, left panel). As a sensitivity analysis, we
performed a conditional logistic regression test accounting for matching between cases
and controls and observed a trend toward higher levels of Env-speciﬁc IgG in the ECs
(adjusted P value [P=]  0.069). We also observed higher Vpu protein-speciﬁc IgG
responses in the EC cohort (P  0.086 and P=  0.027) (Fig. 1A, middle panel). We had
previously mapped an antibody response to the Vpu protein to a C-terminal 13-mer
linear peptide (termed “Vpu19” since it is the 19th of 19 overlapping Vpu peptides
previously studied) (20). We found that ECs had signiﬁcantly higher levels of Vpu19-
Madhavi et al. Journal of Virology
September 2017 Volume 91 Issue 18 e00700-17 jvi.asm.org 2
 o
n
 August 1, 2018 by UQ Library
http://jvi.asm.org/
D
ow
nloaded from
 
speciﬁc antibodies than viremic subjects (P  0.0001 and P=  0.002) (Fig. 1A, right
panel).
Certain HLA I alleles, particularly HLA-B57, -B27, and -B51 play an important role in
controlling HIV through CD8 T cells and are enriched in EC cohorts (3). It has been
postulated that ECs without protective HLA I alleles may be more enriched for non-CD8
T-cell responses capable of controlling HIV (21). Six of the 20 ECs tested had one of
these three beneﬁcial HLA I alleles (Table 1), and we therefore compared these 6 ECs
to the other 14 ECs without beneﬁcial HLA I alleles and to the viremic subjects for Env
and Vpu antibody responses. We did not observe any overall difference in the binding
antibodies against HIV Env and Vpu within the two EC subgroups, although there was
a trend toward higher Vpu protein-speciﬁc antibody responses in the EC cohort without
protective HLA I alleles (Fig. 1B, middle panel). Furthermore, the subset of ECs without
protective HLA I alleles continued to have signiﬁcantly higher levels of binding anti-
bodies against Vpu19 than viremic subjects (P  0.05) (Fig. 1B, right panel).
ECs have high levels of FcRIIIa-binding antibodies to HIV Env and Vpu
compared to those of viremic subjects. There is increasing interest in antibodies to
HIV Env with Fc-mediated functions, although the protective importance of such
TABLE 1 Cohort characteristics
Parameter
Valuea for:
Elite controllers Viremic subjects
No. of subjects 22 44
HIV load, copies/ml 65% of VLs below detection limitb 107,583 (12,449–740,839)
CD4 count, cells/l 880 (337–2,475) 303 (113–490)
Duration of infection, yr 11.3 (2.0–24.0) 6.5 (2.1–21.5)
HIV-1 subtype(s) B (n  13), not done (n  9) B (n  39), C (n  5)
Gender 4 female, 18 male 8 female, 36 male
Age, yr 46 (34–61) 41 (23–62)
Favorable HLA 6 of 20 tested (2 B27, 3 B57, 2 B51) Not tested
aUnless indicated otherwise, values are means with ranges in parentheses.
bSee Table 2.
TABLE 2 Longitudinal VL data for all ECs
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functional antibodies to non-Env proteins is not clear. Measuring Fc-mediated antibody
function is difﬁcult to standardize because of genotypic differences and the variable
activation statuses of effector cells. Further, many ﬂow cytometry-based assays are low
throughput and are not well suited for studying multiple antigens in larger cohorts.
To quantitate antibodies capable of binding FcR, we recently developed a high-
throughput enzyme-linked immunosorbent assay (ELISA)-based assay to measure the
ability of inﬂuenza virus-speciﬁc ADCC antibodies to bind dimeric recombinant soluble
FcRIIIa (rsFcRIIIa) ectodomains (22–24). We adapted this assay to study the ability of
HIV-speciﬁc antibodies to bind higher-afﬁnity dimeric rsFcRIIIa (Fig. 2A) and found that
anti-HIV Env antibodies in the sera of ECs bound the dimeric rsFcRIIIa more potently
than antibodies in the sera of viremic subjects (P  0.0001 and P=  0.002) (Fig. 2B, left
panel).
Furthermore, there was a trend toward higher dimeric rsFcRIIIa binding for Vpu
protein (P  0.073 and P=  0.010) (Fig. 2B, middle panel) in EC sera than in sera from
viremic subjects. We also found that antibodies to the Vpu19 peptide in ECs bound the
FIG 1 Elite controllers (ECs) have high levels of total anti-HIV IgG antibodies compared to those of viremic subjects. (A) Total IgG antibodies binding to HIV Env
(left panel), Vpu protein (middle panel), and Vpu19 peptide (right panel) in ECs (n  22) and viremic subjects (n  44) using a 1:10 serum dilution. All data
were normalized to 5 g/ml HIV IgG immunoglobulin. Bars represent medians (P values, Mann-Whitney U test). (B) Comparison of total IgG-binding antibodies
against HIV Env (left panel), Vpu protein (middle panel), and Vpu19 peptide (right panel) in ECs carrying protective versus nonprotective HLA I to those in viremic
subjects. Bars represent medians (P values, Kruskal-Wallis test). For both panels, the dashed lines represent three times the mean OD obtained using ﬁve
different HIV-negative serum samples against each antigen tested.
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dimeric rsFcRIIIa more potently than those in viremic subjects’ sera (P  0.036 and
P=  0.014) (Fig. 2B, right panel). When comparing protective- versus nonprotective-
HLA-carrying ECs, we did not see any differences in the dimeric rsFcRIIIa-binding
antibodies against HIV Env (Fig. 2C, left panel), Vpu protein (Fig. 2C, middle panel), or
Vpu19 peptide (Fig. 2C, right panel) within the two EC subgroups.
FcR binding is inﬂuenced by several factors other than the amount of antibody,
including IgG-Fc proximity, glycosylation, and antibody subtype. We surmised that the
potency of dimeric rsFcRIIIa binding may be distinct from antibody concentration and
therefore performed endpoint titrations using half-log dilutions of sera against the HIV
Env in a subset of 10 ECs and their 20 matched viremic subjects. For the samples at a
1:10 dilution, a normalized optical density (OD) threshold of 0.455 for the dimeric
rsFcRIIIa-binding activity almost evenly divided the viremic subjects into high- and
low-FcR-activity groups (see the receiver operator curve [ROC] analysis in Materials and
Methods). As previously (Fig. 2B), most of the ECs had high FcR activity above this
threshold (80%) (Fig. 2D). Interestingly, however, endpoint titration showed similar total
levels of Env-speciﬁc dimeric rsFcRIIIa-binding antibodies in ECs and viremic subjects
(Fig. 2E). The higher levels of Env-speciﬁc dimeric rsFcRIIIa-binding antibodies at low
serum dilutions (1:10) despite similar overall titers may suggest greater breadth of
epitope coverage in the ECs, consistent with our previous ADCC studies in slow
progressors (9, 10). Alternatively, this improved EC plasma binding to the rsFcRIIIa
could suggest that EC plasma either binds gp140 more effectively or binds the
rsFcRIIIa more effectively.
EC antibodies dissociate from gp140 more slowly than antibodies from viremic
subjects. We postulated that the mechanism of improved gp140-speciﬁc binding to
the rsFcRIIIa observed in the EC cohort could be through improved plasma antibody
binding to gp140 and/or more effective binding to rsFcRIIIa. To evaluate these
possibilities, we developed a novel surface plasmon resonance (SPR) assay using
polyclonal IgG puriﬁed from plasma to study both interactions. Puriﬁed IgG from ECs or
viremic subjects was ﬁrst passed across and allowed to bind to AD8 Env-gp140
immobilized onto the SPR chip. Following partial dissociation of bound IgG from the
antibody-Envgp140 complex, dimeric rsFcRIIIa was injected to probe the FcRIIIa-
binding activity of the Env-speciﬁc IgG. As it is not practical to isolate Env-speciﬁc IgG
from the patient samples, we puriﬁed and quantitated the total IgG from the samples
using “melon” afﬁnity chromatography. Figure 3A shows an example of data form
dilutions of EC and viremic subjects’ IgG samples.
The complex polyclonal nature of the samples and the multivalent interactions of
Env trimer with bivalent antibodies result in kinetics that cannot be strictly interpreted
with simple deﬁned binding models. Nonetheless, SPR analysis is highly informative, in
particular, the dissociation rate (kd), which is a concentration-independent measure-
ment that can be examined quantitatively in polyclonal IgG preparations (25). We
observed that the rate of IgG binding to Env was slower for the ECs than for the viremic
subjects (Fig. 3B). However, since binding rates are related to analyte concentration, this
could occur with lower concentrations of Env-speciﬁc IgG in the EC samples of total
puriﬁed IgG and/or by a functional difference in recognition of Env protein by these
antibodies.
FIG 2 ECs have higher levels of dimeric rsFcRIIIa-binding antibodies than viremic subjects, (A) Dimeric rsFcRIIIa-binding assay setup. HIV antigen
(50 ng/well) was applied to a 96-well MaxiSorp plate, followed by addition of 1:10 diluted serum (containing IgGs). Subsequently, biotinylated dimeric
rsFcRIIIa was added, binding between antibodies and dimeric rsFcRIIIa was measured using HRP-conjugated streptavidin and TMB, and reaction
stopped with HCl. Absorbance was measured at 450 nm. (B) Dimeric rsFcRIIIa V158-binding antibodies detected in ECs (n  22) compared to those
of viremic subjects (n  44) against HIV Env (left panel), Vpu protein (middle panel), and Vpu19 peptide (right panel) using a 1:10 serum dilution; for
Env, the dotted line at OD  0.455 represent a cutoff of dimeric rsFcRIIIa-binding activity calculated using ROC analyses. All data were normalized
to 5 g/ml HIV IgG immunoglobulin. Bars represent medians (P values from Mann-Whitney U test). (C) Comparison of dimeric rsFcRIIIa V158-binding
antibody responses in ECs carrying protective versus nonprotective HLA I to those in viremic subjects. Bars represent medians (P values, Kruskal-Wallis
test). For both panels B and C, the dashed lines represent three times the mean OD obtained using ﬁve different HIV-negative serum samples against
each antigen tested. (D) Endpoint titration curves of dimeric rsFcRIIIa V158 binding to half-log dilutions of sera against HIV Env for 10 ECs (left panel)
and case-matched 20 viremic subjects (right panel); the dotted lines at OD 0.455 represent a cutoff for dimeric rsFcRIIIa binding activity calculated
using ROC analyses of the data shown in panel B. (E) Dimeric rsFcRIIIa V158-binding antibody endpoint titer comparison of ECs with viremic subjects.
Bars represent medians (P values, Mann-Whitney U test).
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However, of interest, the dissociation of the EC Env-speciﬁc IgG was slower than that
of Env-speciﬁc IgG from the viremic subjects (median kd [1/s] 1.01 105 for ECs and
0.00131 for viremic subjects). This may have functional importance for the EC Env-
speciﬁc IgG, possibly reﬂecting more stable prolonged opsonization of Env protein,
thereby enhancing the opportunities for IgG to engage and activate FcR-bearing cells.
When ka/kd values were plotted as a measure of the apparent binding activities,
there was no apparent difference between the two cohorts. In addition, when binding
of the dimeric rsFcRIIIa to Env-speciﬁc IgG complexes was examined, there was no
apparent difference in the kinetics of binding to IgG from the ECs or the viremic
subjects (Fig. 3C).
Higher levels of antibody-mediated NK cell activation in ECs than in viremic
subjects. In order to corroborate our ﬁnding using a dimeric rsFcRIIIa binding assay
with a functional ADCC assay, we ﬁrst performed antibody-mediated NK cell activation
assays. This assay studies the ability of Env- or Vpu-speciﬁc antibodies to induce
cytokine (gamma interferon [IFN-]) expression and/or degranulation (CD107a expres-
sion) in gated NK cells (9, 26). We found that Env-speciﬁc antibodies in the sera of ECs
induced a higher proportion of NK cells to express IFN- and/or CD107a than those in
FIG 3 EC antibodies dissociate from gp140 more slowly than antibodies from viremic subjects. (A) Surface
plasmon resonance (SPR) experiments were run to determine apparent association (ka) and dissociation (kd)
for each sample across a gp140 protein-coated chip. (B and C) IgG-binding activity to gp140 (B) and FcRIIIa
dimer binding activity to gp140-speciﬁc IgG that remained associated with the gp140 protein chip (C) were
calculated using the BIAevaluation program, and differences between ECs and viremic subjects were
measured using Mann-Whitney nonparametric t tests.
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the sera of viremic subjects (P  0.0006 and P=  0.009) (Fig. 4A, left panel). We also
studied the capacity of Vpu19 peptide-speciﬁc antibodies to induce NK cell activation
in both groups and that found sera from the ECs had higher levels than those from
viremic subjects (P  0.005 and P=  0.014) (Fig. 4C, left panel). When comparing the
effect of protective- versus nonprotective-HLA-carrying ECs, there were no signiﬁcant
differences between these EC subgroups against either HIV Env (Fig. 4B) or the Vpu19
peptide (Fig. 4D).
To dissect the ability of the antibodies to differentially stimulate killing functions
through degranulation as represented by CD107a expression and cytokine secretion via
IFN- expression, we analyzed NK cell expression of IFN- and CD107a against Env and
Vpu19 separately in ECs compared to viremic subjects. We found signiﬁcantly high
IFN- as well as CD107a expression by NK cells against Env stimulation in ECs compared
to viremic subjects (Fig. 4A, middle and right panels). We also found higher CD107a
expression by NK cells against Vpu19 stimulation in ECs compared to viremic subjects
(Fig. 4C, right panel); however, the Vpu19 antibody-stimulated IFN- expression did not
differ between the two groups (Fig. 4C, middle panel).
In vitro ADCC-mediated killing is higher in ECs than in viremic subjects.
Antibody clustering of FcRs and subsequent NK cell activation are necessary steps
FIG 4 Higher levels of antibody-mediated NK cell activation in ECs than in viremic subjects. (A and C) Antibody-mediated NK cell activation to HIV Env (A) and
Vpu19 peptide (C) in ECs (n  22) compared with viremic subjects (n  44) using a 1:4 serum dilution. Bars represent medians (P values, Mann-Whitney U test).
(B and D) Comparison of NK cell activation responses in ECs carrying protective versus nonprotective HLA I to those in viremic subjects. Bars represent medians
(P values, Kruskal-Wallis test). The dashed lines represent three times the mean of background responses obtained using sera from ﬁve different HIV-negative
donors against each antigen tested.
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toward granzyme B delivery to HIV Env-expressing target cells. To more directly study
antibody-mediated granzyme B delivery to target cells, we employed the ADCC-
GranToxiLux (ADCC-GTL) assay, which measures the entry of granzyme B into target
cells as a surrogate of ADCC-mediated killing (27). In the ADCC-GTL assay, we found
that Env-speciﬁc antibodies in the sera of ECs induced a higher granzyme B activity
than those in sera of viremic subjects (P  0.0074 and P=  0.014) (Fig. 5A). When
comparing the effect of protective- versus nonprotective-HLA-carrying ECs, there were
no signiﬁcant differences between these EC subgroups (Fig. 5B).
The rapid ﬂuorometric ADCC (RFADCC) assay is another antibody-mediated func-
tional assay that measures the loss of integrity of Env-coated target cells by measuring
the uptake of target cell membrane by monocytes (28). Using the RFADCC assay, we
observed only a weak trend toward increased uptake of Env-coated target cell mem-
brane by gated monocytes (PKH26 CD3 CD14) in the sera of ECs compared to
those of viremic subjects (P  0.139 and P=  0.296) (Fig. 6A). When comparing
protective- versus nonprotective-HLA-carrying ECs, we did not see any difference in the
killing within the two EC subgroups (Fig. 6B).
DISCUSSION
The investigation of ECs, who naturally control HIV infection, may provide valuable
insights into immune correlates of protection from disease progression. Several viral,
FIG 4 (Continued)
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genetic, and immunological factors are involved in HIV control (3, 17, 29–32). The role
of HIV-speciﬁc ADCC is gaining prominence following post hoc analyses of the partially
successful RV144 trial (33–35). There is increasing evidence from studies in both
humans and macaques that correlate robust ADCC responses with slow disease pro-
gression (9, 10, 36, 37). ADCC responses have also been shown to develop rapidly
following infection with HIV-1, which suggests that these responses could contribute to
HIV control at the early stages of infection (38, 39). We previously showed a role for
FIG 5 ADCC-mediated killing is higher in ECs than in viremic subjects in the ADCC-GTL assay. (A) ADCC-mediated
killing (percent granzyme B activity) of HIV Env-coated targets in the presence of 1:1,000 diluted sera from ECs (n
22) compared to that in viremic subjects (n  44). Bars represent medians (P values, Mann-Whitney U test). (B)
Comparison of percent granzyme B activity in ECs carrying protective versus nonprotective HLA I to that in viremic
subjects. Bars represent medians (P values, Kruskal-Wallis test). For both panels, the dotted lines represent three
times the mean of background responses given by ﬁve HIV-negative serum samples against HIV Env.
FIG 6 ADCC-mediated killing in ECs compared to that in viremic subjects in the RFADCC assay. (A) ADCC-mediated
killing (percent PKH26 CD3 CD14 monocytes) of HIV Env-coated targets in the presence of 1:100 diluted sera
from ECs (n  22) compared to those from viremic subjects (n  44). Bars represent medians (P values,
Mann-Whitney U test). (B) Comparison of the percent PKH26 CD3 CD14 monocyte responses in ECs carrying
protective versus nonprotective HLA I to those in viremic subjects. Bars represent medians (P values, Kruskal-Wallis
test). For both panels, the dashed lines represent three times the mean of background responses given by ﬁve
HIV-negative serum samples against HIV Env.
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ADCC in HIV control in viremic controllers (9, 10, 40). However, data on the role for
ADCC in ECs is limited. Lambotte et al. found that ECs had high levels of HIV
Env-speciﬁc ADCC, whereas levels of NAbs were lower than those in viremic subjects
(7). More recently, Ackerman et al. found polyfunctional antibody effector activity in ECs
but not enhanced antibody responses compared to those in viremic subjects (41). Our
data add weight to the concept that ADCC antibodies can assist durable suppression
of HIV replication.
HIV Env is a key target for an effective antibody-based HIV vaccine, but its high
genetic variability poses a large hurdle to vaccine design. Immune escape from broadly
neutralizing antibodies that are directed against the surface-exposed parts of free
virions is the norm (42). We previously showed Env escape from ADCC, and it is possible
that immune escape reduced our detection of Env ADCC in viremic subjects (16). ECs
may have less immune escape from ADCC responses, since there is so little virus
replication and likely minimal evolution. Env-speciﬁc cytotoxic T lymphocytes (CTLs) are
relatively less effective than Gag-speciﬁc CTL responses in controlling HIV (43, 44). We
studied HIV Env-speciﬁc ADCC antibody responses in ECs compared to viremic subjects
and found that ECs have more potent Env-speciﬁc ADCC responses than viremic
subjects. This is despite the fact that ECs have less antigenic stimulation through
undetectable plasma viral loads (VLs). A potential limitation of our functional assays is
that we studied Env protein-pulsed target cells, and further work studying ADCC on
HIV-infected cells, as a more relevant target, is warranted.
The dimeric rsFcRIIIa ELISA-based assay to measure the binding of HIV-speciﬁc
antibodies to FcRIIIa is a relatively novel approach to studying functional antibodies
for HIV, having previously been used to study inﬂuenza virus-speciﬁc antibodies
(22–24). Commonly used ADCC assays can be difﬁcult to reproduce across laboratories
due to variability of effector and target cells, and they are difﬁcult to perform on a large
scale. The ELISA-based assay using soluble dimeric rsFcRIIIa to detect the presence of
HIV-speciﬁc ADCC antibodies in patient sera is robust and high throughput, and
broadly consistent differences were observed between ECs and viremic subjects with
the NK cell activation and ADCC killing assays. The dimeric rsFcRIIIa detects pairs of
closely spaced IgGs, and such antibodies may comprise some of the opsonizing
antibodies that effectively cross-link FcRIIIa and induce NK cell activation. The assay is
rapid and easy to perform and does not require use of effector cells. This assay may
prove useful for high-throughput analyses of future vaccine trials.
Using the dimeric rsFcRIIIa ELISA-based assay, we found that EC sera had greater
capacity for both IgG binding to Env protein and binding of the IgG-opsonized Env to
the dimeric rsFcRIIIa, together suggesting a broader coverage of Env-speciﬁc epitopes
in the B-cell response of the ECs. The lack of differences between endpoint titers of
these antibodies in ECs compared to viremic subjects likely indicates that, although
broader in epitope coverage, the EC Env-speciﬁc antibodies are not necessarily char-
acterized by superior titer. This novel assay highlights that the quality of the antibody
response with Fc-mediated function may be as important as or more important than
the titer of the response. Future studies identifying conserved Env-speciﬁc ADCC
epitopes commonly targeted by ECs could assist in designing improved HIV vaccines.
In addition, our SPR studies allowed us to examine the binding activity of Env-
speciﬁc IgG from ECs and viremic subjects. The SPR data were ﬁtted to the simplest 1:1
Langmuir binding model, but due to the polyclonal nature of patient IgG and the
complexities of bivalent antibody binding to trimeric gp140 Env, this approach was
only descriptive and not intended to be interpreted mechanistically. Nonetheless, the
apparent dissociation rate, which is concentration independent, can be compared
between samples. The signiﬁcantly lower dissociation rates of Env-speciﬁc IgG of ECs
suggest that these EC IgGs may have a prolonged ability to opsonize Env antigens,
allowing for longer formation of immune complexes and increased opportunities for
FcR engagement activation of FcR-bearing innate immune cells. Interestingly, we did
not observe any intrinsic differences in the FcR-binding activity of Env-speciﬁc IgG
immune complexes by this SPR assay in the cohorts studied. However, highly functional
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forms of IgG have been identiﬁed in spontaneous HIV controllers, for example, en-
hanced levels of afucosylated IgG (45) and isotypes such as IgG3, which have a more
ﬂexible hinge region (41), that can strongly enhance binding to FcRIIIa and improve
ADCC, which may not be apparent in these small quantities of bulk IgG.
We found Vpu-speciﬁc ADCC responses in ECs, consistent with our previous work on
slow progressors (10). HIV Vpu is a crucial viral transmembrane protein that serves two
important functions to promote HIV replication inside the host: (i) CD4 degradation to
evade immune recognition and (ii) virus release by antagonizing the host restriction
factor tetherin (46, 47). Tetherin is important for preventing HIV release and has more
recently been shown to restrict cell-to-cell transmission of HIV (48, 49). Recent studies
have identiﬁed a major role for Vpu in limiting Env expression on the surface of
HIV-infected cells. The ability of Vpu to inhibit tetherin expression on the surface of
infected cells reduces the binding and recognition of ADCC antibodies and thereby
may protect infected cells from ADCC (50–52, 62). If ADCC antibody recognition of Vpu
can disable Vpu-mediated tetherin inhibition, it would enhance the functionality of
Env-speciﬁc ADCC antibodies and could signiﬁcantly contribute to HIV control. In our
IgG-ELISA and dimeric rsFcRIIIa ELISA-based assay, while screening the cohort using
the whole puriﬁed Vpu protein we detected some ECs with ADCC antibody responses
to whole Vpu protein but not to Vpu19 peptide. This suggests that some antibodies
might be targeting an extracellular domain of Vpu that could interfere with interactions
with tetherin, thereby counteracting the antagonistic effect of Vpu. The importance of
immune targeting of Vpu has further been noted by Alter et al., who described
mutations within Vpu that are linked to recognition of Vpu-expressing cells for direct
killing by speciﬁc NK cell subsets (53). The role of CTLs targeting Vpu has also been
described previously (54). Taken together, the data suggest that Vpu is a potentially
useful target for anti-HIV immune responses. Ongoing work to generate and test the
ADCC function of Vpu-speciﬁc monoclonal antibodies is under way. We acknowledge
that our work on both Env- and Vpu-speciﬁc ADCC does not prove a causal link
between ADCC and EC status. Interventional passive-transfer studies in macaques are
suggestive of a role for ADCC function in addition to neutralization capacity in
prevention and control of simian-human immunodeﬁciency virus (SHIV) infection (55,
56), and further passive-transfer studies in macaques and humans should provide more
deﬁnitive evidence.
In summary, elite control of HIV is a multifactorial phenomenon, and our ﬁndings
suggest that ECs have strong ADCC responses to HIV Env and Vpu compared to those
of viremic subjects. Prolonged binding of EC antibodies to Env may allow for the more
effective engagement of FcRs. Novel targets for ADCC antibodies to conserved HIV
antigens such as Vpu may be relevant to target HIV with preventative and therapeutic
vaccines.
MATERIALS AND METHODS
Study cohort. The clinical characteristics of the 22 elite controllers (ECs) and 44 viremic subjects are
shown in Table 1. ECs were deﬁned as having over 65% of the plasma HIV RNA measurements taken as
below the detection limit in the absence of ART. An average of 88.6% of all viral loads (VLs) across ECs
were below the limit of detection as determined by commercial HIV RNA assays used in practice at the
time (VLs ranged from 400 copies/ml in past years to 20 copies/ml more recently). All subjects were
followed for at least 3 months. Longitudinal data for all the ECs are collated in Table 2. ECs (predomi-
nantly having HIV-1 subtype B) were recruited in Australia, both in Melbourne through the Melbourne
Sexual Health Centre and Alfred Health (10 subjects) and in Sydney through Sydney LTNP cohort (12
subjects) (10). ECs were 1:2 case matched to the viremic subjects based on age (window of 5 years),
gender, subtype of HIV, and duration of infection. This case-control matching design enables comparison
of outcomes among ECs and viremic subjects while reducing bias due to confounding variables. The
viremic subjects with VLs of 10,000 copies/ml were recruited from subjects enrolled in the ENCORE1
clinical trial of reduced-dose efavirenz (57, 58). We studied 44 viremic subjects from baseline visit prior
to initiation of ART (mean plasma HIV RNA of 5.1 log10 copies/ml). Healthy HIV-negative volunteers
provided the donor whole blood and peripheral blood mononuclear cells (PBMCs). Research was
conducted under the auspices of the Alfred Human Health Research Ethics Committee for the Melbourne
EC cohort, the St Vincent’s Sydney Human Research Ethics Committee for the Sydney EC cohort, and
participating institutional review boards at all recruiting sites for the ENCORE1 trial.
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HIV antigens. HIV Env (subtype B, strain AD8 gp140) protein and a control simian immunodeﬁciency
virus (SIVMAC239 gp140) Env protein were produced from stable Env-expressing HeLa cell lines, using
previously published techniques (59). HIV Vpu protein was kindly provided by Stanley Opella, University
of California, San Diego (60). HIV Vpu19 peptide was obtained from the NIH AIDS Reagent Program
(catalog number 6444).
Anti-HIV IgG ELISA. ELISA was used to measure the HIV Env- and Vpu-speciﬁc serum IgG titers.
Brieﬂy, HIV antigen in coating buffer (20 mM Tris [pH 8.8], 100 mM NaCl) was applied to 96-well ﬂat
bottom plates at 100 ng/well and left overnight. After blocking with 5% bovine serum albumin (BSA)
(Sigma-Aldrich) containing 0.1% Tween for 2 h, sera were added at a 1:10 dilution. After 90 min of
incubation, horseradish peroxidase (HRP)-conjugated rabbit anti-human IgG antibody (Sigma) was added
and incubated for 1 h. Color reactions were developed using 3,3=,5,5=-tetramethylbenzidine (TMB) and
absorbance measured at 450 nm. Data were normalized to 5 g/ml HIV IgG (HIVIG) (obtained from the
NIH AIDS Reagent Program) diluted in phosphate-buffered saline (PBS). A positive signal was deﬁned as
one giving an OD higher than three times the mean OD obtained using sera from ﬁve HIV-negative
donors against each antigen tested.
Dimeric rsFcRIIIa-binding assay. HIV antibody binding to Fc receptors was measured in vitro
using a dimeric recombinant soluble FcRIIIa (rsFcRIIIa)-binding assay recently described as a sensitive
measure of inﬂuenza virus-speciﬁc ADCC antibodies (22–24). This novel assay uses dimeric rsFcRIIIa
proteins to evaluate the cross-linking of pairs of antibody Fc by FcRs, thereby modeling their potential
to activate effector cells. Ninety-six-well MaxiSorp ELISA plates (Nunc, Rochester, NY) were coated with
50 ng/well of HIV antigens (NIH AIDS Reagent Repository) in PBS overnight at 4°C. Wells were washed
with PBS containing 0.05% Tween 20 (U-CyTech) and blocked with PBS containing 1 mM EDTA and 1%
human serum albumin for 1 h at 37°C. Plates were washed and incubated with 1:10 diluted sera for 1 h
at 37°C and then with 0.1 g/ml of biotinylated dimeric rsFcRIIIa diluted in PBS containing 1 mM EDTA
and 1% BSA (Sigma-Aldrich) for 1 h at 37°C. Subsequently, 100 ng/ml of Pierce high-sensitivity
streptavidin-HRP (Thermo Scientiﬁc, Pittsburgh, PA) diluted in PBS with 1 mM EDTA and 1% BSA was
added and left for 1 h at 37°C. Lastly, TMB substrate (Sigma-Aldrich) was added and color development
stopped with 1 M hydrochloric acid. Absorbance was read at 450 nm. Data were normalized to 5 g/ml
HIVIG diluted in PBS. A positive signal was deﬁned as one giving an OD higher than three times the mean
OD obtained using sera from ﬁve HIV-negative donors against each antigen tested.
SPR. Surface plasmon resonance (SPR) measurements were conducted in HBS-EP buffer (0.01 M
HEPES [pH 7.4], 0.15 M NaCl, 3 mM EDTA, 0.005% [vol/vol] surfactant P20) using a BIAcore 3000 system
(BIAcore AB). IgG was puriﬁed from 10 ECs and 10 matched viremic subjects using the melon gel IgG
puriﬁcation kit (Thermo Fisher Scientiﬁc) according to the manufacturer’s instructions. To assess binding
afﬁnity of sample puriﬁed IgG to gp140 AD8 recombinant protein, biotinylated gp140 AD8 was
immobilized onto an SA sensor chip to approximately 300, 500, and 800 response units (RU). A blank
coupled ﬂow cell with no immobilized ligand was used as a reference ﬂow cell. Injections of 60 l of
puriﬁed subject IgG diluted in PBS to 1:3 dilutions ranging from 0.5 to 0.006 mg/ml were passed across
all ﬂow cells at a ﬂow rate of 20 l/min, with a subsequent 3-min dissociation time to allow for sufﬁcient
time to determine gp140-speciﬁc IgG disassociation (kd) but not long enough for all antibody to
dissociate. Immediately after, 10 l of dimeric rsFcRIIIa (10 g/ml) was injected to measure FcR dimer
binding to and dissociation from the gp140-IgG complex. Regeneration after each injection used two
pulses of 10 l of 10 mM glycine·HCl, pH 3.0. Raw sensograms were corrected by double referencing
(subtracting from the reference ﬂow cell response and from the PBS injection response). Kinetic data
were calculated using the BIAevaluation program. Since the interactions are more complex than the
available models, gp140-speciﬁc data were ﬁtted to the simplest 1:1 binding Langmuir model. The
evaluation of dimeric rsFcRIIIa binding used a 1:1 model with drifting baseline to account for
the continuous dissociation of Env-speciﬁc IgG from the immobilized gp140.
Antibody-mediated NK cell activation assay. The intracellular staining of IFN- and CD107a was
used to detect antibody-mediated NK cell activation as described previously (9). In brief, 150 l of
HIV-negative healthy donor whole blood (from a single healthy donor) and 50 l HIV-infected serum
were incubated at 37°C with HIV Env or Vpu19 peptide (1 g/ml ﬁnal concentration) for 5 h in the
presence of brefeldin A (ﬁnal concentration, 10 g/ml; Sigma), monensin (ﬁnal concentration, 10 g/ml;
BD Biosciences), and APC-H7-conjugated anti-CD107a antibody (clone H4A3; BioLegend). Following
incubation, cells were surface stained with peridinin chlorophyll protein (PerCP)-conjugated anti-CD3
(clone SK7; BioLegend) and phycoerythrin (PE)-Cy7-conjugated anti-CD56 (clone HCD56; BioLegend)
antibodies. Next, whole blood was treated with lysing solution (BD Biosciences) to remove red blood
cells, and the remaining white blood cells were treated with permeabilization solution (BD Biosciences)
and stained with allophycocyanin (APC)-conjugated anti-IFN- antibody (clone B27; BioLegend). Flow
cytometry data were collected using a ﬂuorescence-activated cell sorter (FACS) LSR II ﬂow cytometer (BD
Biosciences) and were analyzed using FlowJo version 10.0.6 software. NK cells were identiﬁed as CD3
CD56, and responses were considered positive if the response (percentage of NK cells expressing IFN-
or CD107a) was more than three times the mean of the response to HIV Env and Vpu19 against ﬁve
HIV-negative sera.
ADCC-GTL assay. Antibody-dependent cellular cytotoxicity (ADCC) activity mediated by the patient
sera was detected using the previously described GranToxiLux (GTL) cell-mediated cytotoxicity proce-
dure (27). Brieﬂy, 106 CEM.NKr-CCR5 cells were coated with 3 g HIV Env and left for 1 h at room
temperature. Coated CEM.NKr-CCR5 target cells were then labeled with a ﬂuorescent target-cell marker
(TFL4; OncoImmunin, Inc., Gaithersburg, MD) and a viability marker (NFL1; OncoImmunin, Inc.) for 15 min
at 37°C as speciﬁed by the manufacturer. The NK cell line GFP-CD16 (176V) NK-92 (61) was used as
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effector cells at a 5:1 effector-to-target (E:T) cell ratio. The GFP-CD16 (176V) NK-92 cell line was kindly
provided by Kerry Campbell from the Institute for Cancer Research in Philadelphia, PA. Twenty-ﬁve
microliters of each effector and target cell suspension and 75 l of granzyme B substrate (OncoImmunin,
Inc.) were dispensed into each well of a 96-well V-bottom plate. After incubation for 5 min at room
temperature, a 1:1,000 dilution of sera was added and incubated for 15 min at room temperature. The
plates were subsequently centrifuged for 1 min at 300  g and incubated for 1 h at 37°C and 5% CO2.
After two washes with wash buffer, cells were resuspended in 50 l of wash buffer and placed at 4°C,
and data were acquired with the LSRII ﬂow cytometer (BD Bioscience, San Jose, CA) within 2 h. Data
analysis was performed using FlowJo version 10.0.6 software. For all HIV Env responses, the SIV Env
control responses (average of 4.8%) were subtracted. A positive response was deﬁned as a percent
granzyme B activity higher than three times the mean of the response to HIV Env using sera from ﬁve
HIV-negative donors.
RFADCC assay. The rapid ﬂuorometric ADCC (RFADCC) assay was used as previously described (28).
Brieﬂy, 106 CEM.NKr-CCR5 cells were coated with 3 g of HIV Env and left for 1 h at room temperature.
SIV Env-coated CEM.NKr-CCR5 cells were used as a control and were treated identically. Coated
CEM.NKr-CCR5 cells were initially labeled with PKH26 (Sigma) and carboxyﬂuorescein succinimidyl ester
(CFSE) (Sigma). PKH26 CFSE labeled CEM.NKr-CCR5 target cells (2  104) were incubated with human
sera (1:100 ﬁnal dilution) for 30 min at 37°C, followed by addition of 2  105 PBMCs (total volume of 100
l) to achieve an E:T cell ratio of 10:1. Cells were incubated for 4 h at 37°C and then stained with
PerCP-conjugated anti-CD3 (clone SK7; BioLegend) and APC-H7-conjugated anti-CD14 (clone MP9; BD
Biosciences) antibodies. Flow cytometry data were collected using a FACS LSR II ﬂow cytometer (BD
Biosciences). The data analysis was performed using FlowJo version 10.0.6 software and a gating strategy
as previously described (28). The assay readout is percentage of PKH26 CD3 CD14monocytes, which
is the measure of CFSE CD3 CD14 monocytes that acquire the target cell PKH26 dye. For all HIV
Env-speciﬁc responses, the SIV Env control responses (average of 5.7%) were subtracted. A positive
response was deﬁned as higher than three times the mean of the response to HIV Env using sera from
ﬁve HIV-negative donors.
Statistical analysis. Statistical analyses were performed with GraphPad Prism version 6.0 (GraphPad
Software, San Diego, CA) and SPSS version 18 software (IBM, Armonk, NY). For comparisons between ECs
and viremic subjects, an unadjusted P value was derived using nonparametric Mann-Whitney U tests
(referred to here as the P value). As a sensitivity analysis, adjusted P values (P=) were derived using
conditional logistic regression tests accounting for matching between cases and controls. The median
was used to describe the data for Mann-Whitney U tests. For multiple comparisons in Fig. 1B, 2C, 3B, 4B,
and 5B, Kruskal-Wallis tests were performed. A P value of 0.05 was considered to indicate a signiﬁcant
difference. Receiver operator curve (ROC) analysis was performed to establish the dimeric rsFcRIIIa-
binding activity threshold (normalized OD 0.455) that best distinguished between the ECs and viremic
subjects (data analyzed from Fig. 2B, left panel, area under the curve  81.9% and P  0.0001).
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